GlassScriptPhysician profile
Kellie H Booth
NPI 1639868458
$2,891.06
in general payments reported to CMS, 2019-2025
18 companies · $826 in 2025
The $826 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $840 · 2024: $1,225 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.76 | 2023-2025 | |
| Neos Therapeutics, LP | $569.66 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Corium, LLC | $517.38 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $219.92 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $113.46 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.14 | 2024-2025 | Caplyta |
| Tris Pharma INC | $83.43 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $83.43 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $74.71 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $68.25 | 2024 | |
| Collegium Pharmaceutical, INC. | $64.29 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $59.85 | 2023-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $56.06 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $48.38 | 2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $43.40 | 2025 | Fanapt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $39.09 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $38.89 | 2023-2025 | Austedo Xr, Austedo Xr |
| Noven Therapeutics, LLC | $19.96 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.